Do Corticosteroid Injections for the Treatment of Pain Influence the Efficacy of Adenovirus Vector-Based COVID-19 Vaccines?

  • Registration Closed
image

Myth: Corticosteroid injection for the treatment of pain is known to decrease the efficacy of the adenovirus vector-based vaccines for COVID-19.

Learn about the facts surrounding this myth and the best practices to support safe performance of interventional pain procedures in your practice.

Each participant will read the FactFinder and will answer post-test questions to earn continuing medical education (CME) credits.    

This, and all other FactFinders, are also available for free without the CME component.

Authors
Haewon Lee, MD; Jennifer A. Punt, A.B., VMD, PhD; Jaymin Patel, MD; Milan P. Stojanovic, MD; Belinda Duszynski, BS; and Zachary L. McCormick, MD, on behalf of the Spine Intervention Society’s Patient Safety Committee

Copyright   
Materials presented in this activity have been made available by the Spine Intervention Society for educational purposes only. We reserve all rights to such material.

Educational Objectives 
Upon completion of this activity, participants should be able to:

  • Identify best practices to ensure patient safety during interventional pain procedures.
  • Cite the evidentiary basis for risk mitigation strategies in the safe performance of interventional pain procedures.

Disclosure Information 
RELEVANT FINANCIAL RELATIONSHIPS WITH ACCME-DEFINED INELIGIBLE COMPANIES 
Zachary L. McCormick, MD - Author
Consultant: FUSMobile
Research support: Avanos Medical; Relievant Medsystems; EpiMed International

None of the other planners, authors, or reviewers had relevant financial relationships with ACCME-defined ineligible companies.
All relevant financial relationships have been mitigated.

References 
References are provided within the FactFinder.

Accreditation Statement    
The Spine Intervention Society (SIS) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.    

Credit Designation Statement    
SIS designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.    

Date of Activity Release: 04/01/2021    
Date of Activity Expiration: 04/02/2024

Components visible upon registration.